Peculiarities of angiogenesis in clear cell renal cancer

Close metadata

Recommended articles:

Influence of perioperative pharmacological stimulation of angiogenesis with 5-oxymethyluracil on long-term results of myocardial revascularization. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(1):22-28

Secretome of mesenchymal stromal cells of the human heart cultured in the form of spheroids is enriched with angiogenic factors and stimulates angiogenesis in vitro and in vivo. Russian Cardiology Bulletin. 2024;(1):38-46

Endothelial cells control vascular growth via regulation of Notch signaling pathway in mesenchymal stromal cells. Russian Cardiology Bulletin. 2024;(2):32-38

Predicting the risk of decreased ovarian reserve after surgical treatment of patients with deep infiltrative endometriosis using artificial intelligence. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):92-102

A literature search was conducted to review papers on the results of studies of clear cell renal cancer (CCRC) vascularization. Numerous data on the relationship between tumor pathogenesis and its vascularization have been revealed, which indicates the multifactorial nature of CCRC development and the significant role of angiogenesis in this process. It should be taken into account that patients with CCRC may have impaired vessel formation even before tumor development. To evaluate normal and pathologic angiogenesis, a pathohistologic study using immunohistochemistry is certainly necessary. Due to the significant role of angiogenesis in the development and course of CCRC, the use of drugs that suppress the formation of the vascular network in the tumor is relevant and advisable. To date, many drugs have been developed and introduced into clinical practice to inhibit angiogenesis. However, such drugs have not lived up to the expectations placed due to the frequent and rapidly developing drug resistance. Timely detection of pre-tumor and tumor processes, as well as effective treatment of cancer, including CCRC, is possible only with close cooperation between pathomorphologists and oncologists.

Keywords:

clear cell renal cell carcinoma

pathogenesis of renal cancer

prognosis of renal cancer

angiogenesis

vascularization

suppression of angiogenesis

Authors:

Maiborodin I.V.

Institute of Molecular Pathology and Pathomorphology of the Federal Research Center for Fundamental and Translational Medicine;
Institute of Chemical Biology and Fundamental Medicine

ORCID: 0000-0002-8182-5084

Klimachev I.V.

Altai State Medical University

ORCID: 0000-0001-9889-9517

Sheplev B.V.

Institute of Molecular Pathology and Pathomorphology of the Federal Research Center for Fundamental and Translational Medicine

ORCID: 0009-0008-4140-3531

Krasil’nikov S.E.

Institute of Molecular Pathology and Pathomorphology of the Federal Research Center for Fundamental and Translational Medicine

ORCID: 0000-0003-0687-0894

Maiborodina V.I.

Institute of Molecular Pathology and Pathomorphology of the Federal Research Center for Fundamental and Translational Medicine

ORCID: 0000-0002-5169-6373

Received:

21.01.2024

Accepted:

24.04.2024

List of references:

Fateri C, Peta A, Limfueco L, Bui TL, Kar N, Glavis-Bloom J, Roth B, Landman J, Houshyar R. Novel retroperitoneal neovascularity scoring system in renal cell carcinoma tumor staging. J Endourol. 2023;37(3):367-373. https://doi.org/10.1089/end.2022.0338
Park KY, Hefti HO, Liu P, Lugo-Cintrón KM, Kerr SC, Beebe DJ. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma. Integr Biol (Camb). 2021;13(11):259-268. https://doi.org/10.1093/intbio/zyab018
Dell’Atti L, Bianchi N, Aguiari G. New therapeutic interventions for kidney carcinoma: looking to the future. Cancers (Basel). 2022;14(15):3616. https://doi.org/10.3390/cancers14153616
Kaprin AD, Starinskii VV, Shakhzadova AO, eds. The state of cancer care for the population of Russia in 2019. Moscow: MNIOI im. P.A. Herzen — branch of the Federal State Budgetary Institution «National Medical Research Center of Radiology» of the Ministry of Health of Russia; 2020. (In Russ.).
Shevchenko AN, Breus AA, Neskubina IV, Dzhenkova EA, Filatova EV, Shvyrev DA. Evaluation of the prognostic significance of some biological factors in local and generalized clear cell renal cancer. South Russian Journal of Cancer. 2020;1(1):6-22. (In Russ.). https://doi.org/10.37748/2687-0533-2020-1-1-1
Yan H, Zhu L, Zhang J, Lin Z. Histone demethylase KDM4D inhibition suppresses renal cancer progression and angiogenesis through JAG1 signaling. Cell Death Discov. 2021;7(1):284. https://doi.org/10.1038/s41420-021-00682-y
Zhang Y, Chen Z, Chen JG, Chen XF, Gu DH, Liu ZM, Gao YD, Zheng B. Ceruloplasmin overexpression is associated with oncogenic pathways and poorer survival rates in clear-cell renal cell carcinoma. FEBS Open Bio. 2021;11(11):2988-3004. https://doi.org/10.1002/2211-5463.13283
Liu W, Yan B, Yu H, Ren J, Peng M, Zhu L, Wang Y, Jin X, Yi L. OTUD1 stabilizes PTEN to inhibit the PI3K/AKT and TNF-alpha/NF-kappaB signaling pathways and sensitize ccRCC to TKIs. Int J Biol Sci. 2022;18(4):1401-1414. https://doi.org/10.7150/ijbs.68980
Dumond A, Montemagno C, Vial V, Grépin R, Pagès G. Anti-vascular endothelial growth factor C antibodies efficiently inhibit the growth of experimental clear cell renal cell carcinomas. Cells. 2021;10(5):1222. https://doi.org/10.3390/cells10051222
Yoshida T, Ohe C, Ikeda J, Atsumi N, Ohsugi H, Sugi M, Higasa K, Saito R, Tsuta K, Matsuda T, et al. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. J Immunother Cancer. 2021;9(9):e002922. https://doi.org/10.1136/jitc-2021-002922
Mubarak M, Al-Gharaibeh N, Sommaruga S, Li J, Vortmeyer AO. Histological tracking into the third dimension: evolution of early tumorigenesis in VHL kidney. J Kidney Cancer VHL. 2021; 8(3):5-14. https://doi.org/10.15586/jkcvhl.v8i3.189
Takao S, Ushijima Y, Motomura Y, Sakamoto K, Hirakawa M, Nishie A, Mimori K, Yamashita Y, Tsutsumi T, Ishigami K. Radiology- and gene-based risk stratification in small renal cell carcinoma: a preliminary study. PLoS One. 2021;16(9):e0256471. https://doi.org/10.1371/journal.pone.0256471
Xin S, Sun X, Jin L, Zhou Z, Liu X, Li W, Mei W, Zhang J, Zhang B, Yao X, et al. Identifying the potential role and prognostic value of the platelet-derived growth factor pathway in kidney renal clear cell carcinoma. J Oncol. 2022;2022:9498010. https://doi.org/10.1155/2022/9498010
Seo SU, Woo SM, Im SS, Jang Y, Han E, Kim SH, Lee H, Lee HS, Nam JO, Gabrielson E, et al. Cathepsin D as a potential therapeutic target to enhance anticancer drug-induced apoptosis via RNF183-mediated destabilization of Bcl-xL in cancer cells. Cell Death Dis. 2022;13(2):115. https://doi.org/10.1038/s41419-022-04581-7
Karpova Y, Guo D, Makhov P, Haines AM, Markov DA, Kolenko V, Tulin AV. Poly(ADP)-ribosylation inhibition: a promising approach for clear cell renal cell carcinoma therapy. Cancers (Basel). 2021;13(19):4973. https://doi.org/10.3390/cancers13194973
Meng X, Yuan H, Li W, Xiao W, Zhang X. Biomarker screening and prognostic significance analysis for renal cell carcinoma. Int J Gen Med. 2021;14:5255-5267. https://doi.org/10.2147/IJGM.S325347
Bekku K, Tsugawa T, Tsuboi K, Noda G, Inoue Y, Murao W, Ebara S. Molecular-targeted therapy for metastatic renal cell carcinoma as first-line therapy: a single institution 13-year experience. Acta Med Okayama. 2022;76(4):465-472. https://doi.org/10.18926/AMO/63906
Topal A, Sayın S, Gokyer A, Kucukarda A, Kostek O, Bekir Hacıoglu M, Uzunoglu S, Erdogan B, Cicin I. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience. J BUON. 2021;26(4): 1628-1634.
Ohe C, Yoshida T, Amin MB, Atsumi N, Ikeda J, Saiga K, Noda Y, Yasukochi Y, Ohashi R, Ohsugi H, et al. Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes. Mod Pathol. 2022;35(6):816-824. https://doi.org/10.1038/s41379-021-00982-9
Denize T, Farah S, Cimadamore A, Flaifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, et al. Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in patients with metastatic renal cell carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2022;28(4):748-755. https://doi.org/10.1158/1078-0432.CCR-21-3088
Roussel E, Kinget L, Verbiest A, Boeckx B, Zucman-Rossi J, Couchy G, Caruso S, Baldewijns M, Joniau S, Van Poppel H, et al. Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. Acta Oncol. 2021;60(11):1499-1506. https://doi.org/10.1080/0284186X.2021.1962971
Roussel E, Verbiest A, Kinget L, Boeckx B, Zucman-Rossi J, Couchy G, Caruso S, Job S, de Reyniès A, De Wever L, et al. Molecular subtypes and gene expression signatures as prognostic features in fully resected clear cell renal cell carcinoma: a tailored approach to adjuvant trials. Clin Genitourin Cancer. 2021; 19(6):e382-e394. https://doi.org/10.1016/j.clgc.2021.07.005
Situ Y, Xu Q, Deng L, Zhu Y, Gao R, Lei L, Shao Z. System analysis of VEGFA in renal cell carcinoma: The expression, prognosis, gene regulation network and regulation targets. Int J Biol Markers. 2022;37(1):90-101. https://doi.org/10.1177/17246008211063501
Udayakumar D, Zhang Z, Xi Y, Dwivedi DK, Fulkerson M, Haldeman S, McKenzie T, Yousuf Q, Joyce A, Hajibeigi A, et al. Deciphering intratumoral molecular heterogeneity in clear cell renal cell carcinoma with a Radiogenomics Platform. Clin Cancer Res. 2021;27(17):4794-4806. https://doi.org/10.1158/1078-0432.CCR-21-0706
Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grepin R, Rioux-Leclercq N, et al. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy. BJU Int. 2022;129(1):80-92. https://doi.org/10.1111/bju.15506
Li K, Tan L, Li Y, Lyu Y, Zheng X, Jiang H, Zhang X, Wen H, Feng C. Cuproptosis identifies respiratory subtype of renal cancer that confers favorable prognosis. Apoptosis. 2022;27(11-12):1004-1014. https://doi.org/10.1007/s10495-022-01769-2
Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, Maruzzo M, Mosca A, Pisano C, Verzoni E, et al. Combination therapy in renal cell carcinoma: the best choice for every patient? Curr Oncol Rep. 2021;23(12):147. https://doi.org/10.1007/s11912-021-01140-9
Graham J, Wells JC, Dudani S, Gan CL, Donskov F, Lee JL, Kollmannsberger CK, Meza L, Beuselinck B, Hansen A, et al. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. Eur J Cancer. 2022;171:124-132. https://doi.org/10.1016/j.ejca.2022.05.002
Swearson S, Rataan AO, Eliason S, Amendt BA, Zakharia Y, Salem AK, Ho T, Rustum YM. MicroRNA expression in clear cell renal cell carcinoma cell lines and tumor biopsies: potential therapeutic targets. Int J Mol Sci. 2022;23(10):5604. https://doi.org/10.3390/ijms23105604
Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, et al. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022;14(641):eabm6420. https://doi.org/10.1126/scitranslmed.abm6420
Xie Y, Shangguan W, Chen Z, Zheng Z, Chen Y, Zhong Q, Zhang Y, Yang J, Zhu D, Xie W. Establishment of sunitinib-resistant xenograft model of renal cell carcinoma and the identification of drug-resistant hub genes and pathways. Drug Des Devel Ther. 2021;15:5061-5074. https://doi.org/10.2147/DDDT.S343718
Marona P, Górka J, Kwapisz O, Jura J, Rys J, Hoffman RM, Miekus K. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation. Cell Death Dis. 2022;13(9):814. https://doi.org/10.1038/s41419-022-05251-4
Principe DR, Schulte BC, Kamath SD, Munshi HG. Glandular metastases from renal cell carcinoma show poor clinical responses to immune checkpoint inhibition but durable responses to angiogenesis inhibitors. BMJ Case Rep. 2021;14(6):e243259. https://doi.org/10.1136/bcr-2021-243259

Close metadata